Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BIIB

Biogen Inc

Feb 07 • 04:00PM ET

141.35

Dollar change -1.02
Percentage change -0.72	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO VO QQQ COWZ SPY IVV VTV XLV VOE

Scroll to Statements

Index	NDX, S&P 500	P/E	12.77	EPS (ttm)	11.07	Insider Own	0.71%	Shs Outstand	145.70M	Perf Week	-1.79%
Market Cap	20.60B	Forward P/E	8.65	EPS next Y	16.34	Insider Trans	-0.05%	Shs Float	144.68M	Perf Month	-7.70%
Income	1.62B	PEG	2.43	EPS next Q	3.35	Inst Own	92.34%	Short Float	2.61%	Perf Quarter	-20.11%
Sales	9.23B	P/S	2.23	EPS this Y	11.21%	Inst Trans	2.49%	Short Ratio	2.59	Perf Half Y	-29.25%
Book/sh	112.28	P/B	1.26	EPS next Y	-0.20%	ROA	5.72%	Short Interest	3.77M	Perf Year	-42.44%
Cash/sh	11.66	P/C	12.12	EPS next 5Y	5.25%	ROE	10.47%	52W Range	139.71 - 246.44	Perf YTD	-7.57%
Dividend Est.	-	P/FCF	10.58	EPS past 5Y	-18.05%	ROI	7.60%	52W High	-42.64%	Beta	0.01
Dividend TTM	-	Quick Ratio	0.80	Sales past 5Y	-7.03%	Gross Margin	67.77%	52W Low	1.17%	ATR (14)	3.64
Dividend Ex-Date	-	Current Ratio	1.26	EPS Y/Y TTM	9.71%	Oper. Margin	22.96%	RSI (14)	39.94	Volatility	2.45% 2.54%
Employees	7570	Debt/Eq	0.41	Sales Y/Y TTM	-3.98%	Profit Margin	17.50%	Recom	2.03	Target Price	217.52
Option/Short	Yes / Yes	LT Debt/Eq	0.30	EPS Q/Q	665.41%	Payout	0.00%	Rel Volume	0.78	Prev Close	142.37
Sales Surprise	1.29%	EPS Surprise	8.15%	Sales Q/Q	-2.44%	Earnings	Feb 12 BMO	Avg Volume	1.46M	Price	141.35
SMA20	-1.89%	SMA50	-5.78%	SMA200	-26.19%	Trades		Volume	1,136,113	Change	-0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327
Jul-24-23	Reiterated	UBS	Buy	$346 → $335
May-01-23	Upgrade	Guggenheim	Neutral → Buy	$270 → $350
Apr-17-23	Upgrade	Piper Sandler	Neutral → Overweight	$280 → $346

Show Previous Ratings

Feb-07-25 09:15AM	Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
07:32AM	Genentech eyes lupus market for Gazyva with positive Phase III data readout (Pharmaceutical Technology)
Feb-05-25 10:00AM	Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:16AM	Lillys investigational Alzheimers to be investigated in prevention trial (Clinical Trials Arena)
Feb-02-25 08:12AM	Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? (Insider Monkey)
06:30AM	Loading…
Jan-31-25 06:30AM	Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union (GlobeNewswire)
Jan-29-25 12:10PM	Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-28-25 07:28AM	Sage rejects Biogens $469m takeover bid (Pharmaceutical Technology)
Jan-27-25 12:40PM	Sage rebuffs Biogen bid to take it over (BioPharma Dive)
09:28AM	Sage rejects Biogen's $469 million takeover offer, says offer undervalues company (Reuters)
07:12AM	Eisai and Biogens Leqembi sBLA set for Alzheimers maintenance dosing (Pharmaceutical Technology)
07:05AM	FDA clears monthly dosing of Alzheimers drug Leqembi (BioPharma Dive)
Jan-26-25 06:38PM	US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug (Reuters)
06:33PM	FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
Jan-23-25 12:06PM	Biogens higher dose Spinraza under review by US and EU regulators (Pharmaceutical Technology)
09:46AM	Loading…
09:46AM	Eli Lilly Stock Has Tumbled 23% Since Its August High. Is It A Buy Or A Sell? (Investor's Business Daily)
07:30AM	FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA (GlobeNewswire)
Jan-22-25 12:03PM	Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk (Yahoo Finance)
Jan-21-25 06:05AM	Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma (The Wall Street Journal)
Jan-15-25 06:52AM	At JPM, Biogen CEO tries to take down the deal temperature (BioPharma Dive)
06:26AM	Federal watchdog cites concerns with FDAs accelerated approval process (BioPharma Dive)
Jan-14-25 06:00PM	Biogen CEO sees no burning need for more acquisitions (Reuters)
09:41AM	Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist (TipRanks)
09:40AM	Biogen bid for Sage does not change narrative, says BMO Capital (TipRanks)
09:04AM	FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi (Benzinga)
08:06AM	Eisai and Biogens subcutaneous Leqembi set for FDA review (Pharmaceutical Technology)
Jan-13-25 07:05PM	FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
03:12PM	Biogen proposes acquisition of partner Sage Therapeutics (Pharmaceutical Technology)
11:57AM	Top Stock Movers Now: Moderna, Macy's, Valero Energy, and More (Investopedia)
09:56AM	Biogen Wants to Buy Its Partner Sage for Almost No Premium (Barrons.com)
09:51AM	Loading…
09:51AM	Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid (Investopedia)
09:38AM	Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? (Benzinga)
07:24AM	Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen (Barrons.com)
07:07AM	Biogens cold and calculated offer to buy Sage receives a mixed reaction on Wall Street (BioPharma Dive)
Jan-10-25 06:49PM	Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (Business Wire)
06:37PM	Biogen proposes to buy remaining stake in Sage in $442 million deal (Reuters)
09:02AM	Heres Why ClearBridge Growth Strategy Sold Biogen (BIIB) (Insider Monkey)
06:43AM	Pfizers PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets (BioPharma Dive)
06:25AM	Alzheimers Drugs Eyed as Next Big Obesity-Like Opportunity (Bloomberg)
Jan-09-25 08:00AM	Is Eli Lilly Stock A Buy Or A Sell After Its Weight-Loss Drug Scores A Major Victory? (Investor's Business Daily)
Jan-08-25 04:40PM	Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)s Struggles with Alzheimers and MS Challenges? (Insider Monkey)
Jan-04-25 07:45AM	These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024 (Motley Fool)
Jan-02-25 12:03PM	Is Eli Lilly Stock A Buy After FDA Pushes Back On Compounded Knockoffs? (Investor's Business Daily)
09:25AM	Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges (Investing.com)
Jan-01-25 09:40AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
09:37AM	The 5 worst performing stocks on the Nasdaq 100 in 2024 (TheStreet)
Dec-28-24 04:49PM	Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025 (Insider Monkey)
Dec-23-24 05:07AM	Biogen Faces Multiple Analyst Downgrades in December 2024 (GuruFocus.com)
Dec-20-24 09:44AM	BMO cuts rating on Merck and Biogen, on lack of near term catalyst (Investing.com)
Dec-16-24 01:16PM	Stifel downgrades Biogen on slow Alzheimers drug launch, uncertainty ahead (Investing.com)
10:26AM	Netflix, Ford, Biogen: Trending tickers (Yahoo Finance Video)
Dec-13-24 08:00AM	CMS says private Medicare plans cant automatically deny Biogens ALS drug (BioPharma Dive)
Dec-11-24 07:10AM	Biogen reinstated with a Neutral at BofA (TipRanks)
Dec-09-24 01:44PM	Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown (Benzinga)
12:27PM	Biogen cut at Jefferies as '2025 has a tough setup' (Investing.com)
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Dec-04-24 06:31PM	'LEQEMBI' (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico (PR Newswire)
Dec-02-24 07:44AM	Analyst Report: Biogen Inc. (Morningstar Research)
Nov-28-24 06:08AM	Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood? (Insider Monkey)
Nov-27-24 07:31PM	'LEQEMBI' (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea (PR Newswire)
09:15AM	Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024? (Insider Monkey)
Nov-26-24 02:23PM	Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy? (Investor's Business Daily)
Nov-22-24 11:00AM	Is Eli Lilly Stock A Sell After Kennedy-Tied Woes Rankled Shares? (Investor's Business Daily)
07:45AM	Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock (Insider Monkey)
06:45AM	Biogen price target lowered to $207 from $251 at Mizuho (TipRanks)
Nov-20-24 01:32PM	Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside (Benzinga)
Nov-19-24 07:06PM	Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
01:00AM	Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity (GlobeNewswire)
Nov-18-24 01:18PM	Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 (Benzinga)
11:30AM	Needham downgrades Biogen on slow growth of Alzheimer's drug (Investing.com)
07:00AM	Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ (GlobeNewswire)
04:25AM	Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? (Insider Monkey)
12:40AM	Analyst Report: Biogen Inc. (Morningstar Research)
Nov-14-24 02:20PM	European committee takes a second look at Alzheimer's drug and now says it should be approved (Associated Press Finance)
01:53PM	5 Healthcare Stocks to Buy in a Beaten-Up Sector (Barrons.com)
01:29PM	Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease (PR Newswire)
09:54AM	Citi initiates coverage on 5 new biotech stocks (Investing.com)
Nov-12-24 09:40AM	Here's Why Biogen Inc. (BIIB) is a Strong Value Stock (Zacks)
Nov-11-24 06:51PM	Analyst Report: Biogen Inc. (Morningstar Research)
Nov-08-24 09:33AM	Analyst Report: Biogen Inc. (Morningstar Research)
Nov-05-24 09:40AM	Are Investors Undervaluing Biogen (BIIB) Right Now? (Zacks)
Nov-04-24 09:35AM	Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-31-24 08:03PM	Eisai Completes Rolling Submission to US FDA for LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status (PR Newswire)
10:51AM	Biogen down as Morgan Stanley cuts rating on sluggish Alzheimers drug launch (Investing.com)
03:07AM	Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... (GuruFocus.com)
Oct-30-24 07:30PM	Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference (GlobeNewswire)
04:27PM	Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. (Investor's Business Daily)
02:01PM	Analyst Report: Biogen Inc. (Morningstar Research)
01:46PM	Biogen and Neomorph enter molecular glue degrader deal (Pharmaceutical Technology)
01:45PM	Biogen (BIIB) Q3 2024 Earnings Call Transcript (Motley Fool)
09:30AM	Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:05AM	Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates (Zacks)
07:38AM	Biogen, Sage admit a defeat in major depression (BioPharma Dive)
07:28AM	Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum (Investor's Business Daily)
07:18AM	Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations (Yahoo Finance)
07:07AM	Biogen raises annual earnings guidance, tops Q3 estimates; shares up (Investing.com)
07:02AM	Biogen Raises Forecast as Alzheimers Drug Leqembi Shows Signs of Growth (Bloomberg)
06:54AM	Biogen raises annual profit forecast as new treatments boost earnings (Reuters)
06:15AM	Biogen optimistic as new products gain traction (BioPharma Dive)
Oct-29-24 06:00PM	Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases (GlobeNewswire)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Singhal Priya	Head of Development	Jan 31 '25	Option Exercise	0.00	1,828	0	7,254	Feb 03 06:02 PM
Singhal Priya	Head of Development	Dec 06 '24	Option Exercise	0.00	426	0	5,742	Dec 09 04:57 PM
Singhal Priya	Head of Development	Dec 09 '24	Sale	157.21	110	17,293	5,426	Dec 09 04:57 PM
Kramer Robin	Chief Accounting Officer	Dec 06 '24	Option Exercise	0.00	351	0	6,578	Dec 09 04:56 PM
Singhal Priya	Officer	Dec 09 '24	Proposed Sale	157.21	110	17,293		Dec 09 10:33 AM
Grogan Jane	Head of Research	Nov 01 '24	Option Exercise	0.00	695	0	695	Nov 04 04:39 PM
Singhal Priya	Head of Development	Aug 30 '24	Option Exercise	0.00	1,668	0	6,554	Sep 05 06:00 AM
Singhal Priya	Head of Development	Sep 03 '24	Sale	204.22	431	88,019	5,316	Sep 05 06:00 AM
Singhal Priya	Officer	Sep 03 '24	Proposed Sale	204.22	431	88,019		Sep 03 01:00 PM
Keeney Adam	Head of Corporate Development	May 01 '24	Option Exercise	0.00	938	0	938	May 03 08:00 PM
Singhal Priya	Head of Development	Apr 02 '24	Sale	213.09	93	19,817	4,886	Apr 03 08:24 PM
Murphy Nicole	Head of Pharm Ops and Tech	Apr 01 '24	Option Exercise	0.00	240	0	9,751	Apr 03 08:11 PM
Singhal Priya	Head of Development	Feb 22 '24	Sale	221.23	262	57,962	4,886	Feb 26 07:54 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 16 '24	Option Exercise	0.00	5,037	0	52,506	Feb 21 09:39 PM
Gregory Ginger	EVP, Human Resources	Feb 16 '24	Option Exercise	0.00	4,704	0	14,341	Feb 21 09:36 PM
Izzar Rachid	Head of Global Product Strat.	Feb 16 '24	Option Exercise	0.00	2,017	0	10,014	Feb 21 09:33 PM
Kramer Robin	Chief Accounting Officer	Feb 16 '24	Option Exercise	0.00	1,345	0	6,354	Feb 21 09:31 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 16 '24	Option Exercise	0.00	6,720	0	20,692	Feb 21 09:29 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 16 '24	Option Exercise	0.00	1,260	0	9,624	Feb 21 09:28 PM
Singhal Priya	Head of Development	Feb 16 '24	Option Exercise	0.00	1,208	0	5,429	Feb 21 09:27 PM
Singhal Priya	Head of Development	Feb 16 '24	Sale	221.49	108	23,921	5,148	Feb 21 09:27 PM
Rowinsky Eric K	Director	Feb 15 '24	Buy	222.54	455	101,256	20,629	Feb 20 09:13 PM
Gregory Ginger	EVP, Human Resources	Feb 09 '24	Option Exercise	0.00	2,158	0	11,778	Feb 13 06:14 PM
Singhal Priya	Head of Development	Feb 09 '24	Option Exercise	0.00	1,212	0	5,309	Feb 13 06:06 PM
Singhal Priya	Head of Development	Feb 12 '24	Sale	239.45	419	100,330	4,516	Feb 13 06:06 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 09 '24	Option Exercise	0.00	2,272	0	9,529	Feb 13 06:04 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 09 '24	Option Exercise	0.00	3,257	0	17,555	Feb 13 06:03 PM
Kramer Robin	Chief Accounting Officer	Feb 09 '24	Option Exercise	0.00	833	0	5,523	Feb 13 06:01 PM
Izzar Rachid	Head of Global Product Strat.	Feb 09 '24	Option Exercise	0.00	1,515	0	9,081	Feb 13 06:00 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 09 '24	Option Exercise	0.00	2,575	0	50,021	Feb 13 05:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIIB

Biogen Inc

Upgrade your FINVIZ experience